Сравнение

Maridebart Cafraglutide vs. Petrelintide

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Petrelintide

As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Maridebart Cafraglutide	Petrelintide
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Maridebart Cafraglutide

Полная запись →

Petrelintide

Полная запись →

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Petrelintide?: Maridebart Cafraglutide is classified as "Метаболизм", while Petrelintide is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Maridebart Cafraglutide or Petrelintide?: The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "РКИ на людях" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Maridebart Cafraglutide and Petrelintide in Germany and the United States?: Германия: Maridebart Cafraglutide — Не одобрено, Petrelintide — Не одобрено. США: Maridebart Cafraglutide — Не одобрено, Petrelintide — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Maridebart Cafraglutide

Petrelintide

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Petrelintide?

Maridebart Cafraglutide is classified as "Метаболизм", while Petrelintide is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Maridebart Cafraglutide or Petrelintide?

The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "РКИ на людях" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Maridebart Cafraglutide and Petrelintide in Germany and the United States?

Германия: Maridebart Cafraglutide — Не одобрено, Petrelintide — Не одобрено. США: Maridebart Cafraglutide — Не одобрено, Petrelintide — Не одобрено. These are factual summaries with source and review date on the individual pages.